Curaleaf Holdings, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CURLF in the last 30 days.
See all $CURLF insider activity →The DOJ proposed a briefing schedule for marijuana petitions, with final briefs due by Feb. 2027. Curaleaf, with 164 U.S. dispensaries, is involved. Shares closed at C$13.31 on Oct. 9, down 1.41%. The court has not yet adopted the schedule.
Curaleaf Holdings (TSX:CURA) raised its hostile bid for Aurora Cannabis to US$5 per share, aiming to expand in Canada. CURA's stock is up 30.91% year-to-date but down 65.64% over 5 years. Analysts estimate fair value at CA$18.54, 24% above its current price of CA$14.06, citing growth in international markets and revenue forecasts of US$1.7b.
Curaleaf (CURA) raised its offer to acquire Aurora Cannabis (ACB) to US$5 per share, up from US$4. Aurora's board previously rejected the lower bid, calling it undervalued. Curaleaf values Aurora's international business, which saw a 17% increase in its medical cannabis segment. Aurora reported a narrowed loss of US$4 million last quarter, down from nearly US$20 million a year ago.
Over the past 7 days, AlphAI's AI scored 13 news stories mentioning CURLF (Curaleaf Holdings, Inc.). Coverage has been balanced: 3 bullish, 7 neutral, and 3 bearish.
Recent CURLF coverage spans mergers & acquisitions, financial news and regulation.
The filing schedule is a procedural step, but it extends the timeline for merits briefing on the Schedule I to Schedule III transfer that could affect Curaleaf’s regulatory and tax outlook.
Curaleaf Holdings (TSX:CURA) raised its hostile bid for Aurora Cannabis to US$5 per share, aiming to expand in Canada. CURA's stock is up 30.91% year-to-date but down 65.64% over 5 years. Analysts estimate fair value at CA$18.54, 24% above its current price of CA$14.06, citing growth in international markets and revenue forecasts of US$1.7b.
Curaleaf (CURA) raised its offer to acquire Aurora Cannabis (ACB) to US$5 per share, up from US$4. Aurora's board previously rejected the lower bid, calling it undervalued. Curaleaf values Aurora's international business, which saw a 17% increase in its medical cannabis segment. Aurora reported a narrowed loss of US$4 million last quarter, down from nearly US$20 million a year ago.
ECS Botanics (ECS) partners with Curaleaf Laboratories to launch six medicinal cannabis products in the UK. The two-year deal involves ECS supplying Australian-grown flower, with Curaleaf handling local manufacturing and distribution. ECS aims to start supply in November 2026, subject to regulatory approvals, expanding its international branded strategy without local infrastructure.
Curaleaf Holdings, Inc. updated the offering circular for Aurora Cannabis Inc. on October 6, 2026, as announced in a press release. The update was filed with the SEC as part of a Form 8-K.
AlphAI scores every news story that mentions CURLF with an AI model for sentiment and relevance, and aggregates insider trades from Curaleaf Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The DOJ proposed a briefing schedule for marijuana petitions, with final briefs due by Feb. 2027. Curaleaf, with 164 U.S. dispensaries, is involved. Shares closed at C$13.31 on Oct. 9, down 1.41%. The court has not yet adopted the schedule.
5 min readCuraleaf Holdings (TSX:CURA) raised its hostile bid for Aurora Cannabis to US$5 per share, aiming to expand in Canada. CURA's stock is up 30.91% year-to-date but down 65.64% over 5 years. Analysts estimate fair value at CA$18.54, 24% above its current price of CA$14.06, citing growth in international markets and revenue forecasts of US$1.7b.
2 min readCuraleaf (CURA) raised its offer to acquire Aurora Cannabis (ACB) to US$5 per share, up from US$4. Aurora's board previously rejected the lower bid, calling it undervalued. Curaleaf values Aurora's international business, which saw a 17% increase in its medical cannabis segment. Aurora reported a narrowed loss of US$4 million last quarter, down from nearly US$20 million a year ago.
2 min readECS Botanics (ECS) partners with Curaleaf Laboratories to launch six medicinal cannabis products in the UK. The two-year deal involves ECS supplying Australian-grown flower, with Curaleaf handling local manufacturing and distribution. ECS aims to start supply in November 2026, subject to regulatory approvals, expanding its international branded strategy without local infrastructure.
2 min readCuraleaf Holdings, Inc. updated the offering circular for Aurora Cannabis Inc. on October 6, 2026, as announced in a press release. The update was filed with the SEC as part of a Form 8-K.
1 min readCuraleaf Holdings, Inc. (CURLF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 The Offer (as defined herein) has not been approved or disapproved by any securities regulatory authority, nor has any securities regulatory authority in any manner expressed an opinion or passed judgment upon the fairness or merits of the Offer, the securities offer
2 min readAurora Cannabis (ACB) advises shareholders to take no action on Curaleaf's hostile takeover bid, which has yet to be formally revised. Curaleaf's initial offer of $5.00 per share (0.4013 shares + $1.00 cash) is under review by Aurora's special committee. Aurora expects Curaleaf to provide pro forma financials and extend the bid timeline. The board will issue a formal recommendation once the review is complete. Shareholders have until December 4, 2026, to consider their options.
2 min readCannara Biotech has expanded its long-term supply agreement with Curaleaf International. The companies plan to grow together, supplying Québec-grown cannabis to international medical markets. Cannara has 15 of 24 grow rooms active at its Valleyfield facility, with a plan to scale production as demand grows. Curaleaf supports Cannara's EU-GMP certification pursuit for its processing center.
1 min readCuraleaf (CURLF) improved its bid to buy Aurora Cannabis (ACB), offering $5.00 per share. The deal aims to acquire all outstanding common shares of Aurora.
1 min readCannara Biotech (LOVE) expanded its supply agreement with Curaleaf, increasing the potential value to C$34M over two years from C$21M. This is the company's first long-term international supply commitment.
1 min read
